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ABSTRACT (193 words) 
This study aimed at identifying simple rules for allocating COPD patients to clinical phenotypes 
identified by cluster analyses.  
Data from 2409 COPD patients from French/Belgian COPD cohorts were analysed using 
cluster analysis, resulting in the identification of subgroups for which clinical relevance was 
determined by comparing 3-year all-cause mortality. Classification and regression trees 
(CARTs) were used to develop an algorithm for allocating patients to these subgroups. This 
algorithm was tested in 3651 patients from the COPD Cohorts Collaborative International 
Assessment (3CIA) initiative. 
Cluster analysis identified five subgroups of COPD patients with different clinical 
characteristics (especially regarding severity of respiratory disease and presence of 
cardiovascular comorbidities and diabetes). CART-based algorithm indicated that the variables 
relevant for patient grouping differed markedly between patients with isolated respiratory 
disease (FEV1, dyspnoea grade) and those with multimorbidity (dyspnoea grade, age, FEV1 and 
body mass index). Application of this algorithm to the 3CIA cohorts confirmed that it identified 
subgroups of patients with different clinical characteristics, mortality rates (median, from 4% 
to 27%) and age at death (median, from 68 to 76 years).  
A simple algorithm, integrating respiratory characteristics and comorbidities, allowed the 
identification of clinically-relevant COPD phenotypes.  
 
Take home message: An algorithm integrating respiratory characteristics and comorbidities 





Airflow limitation is the hallmark of chronic obstructive pulmonary disease (COPD) and forced 
expiratory volume in one second (FEV1) has long been used as the main criteria for 
characterization of disease severity [1, 2]. Analyses of observational cohorts (e.g., the ECLIPSE 
cohort) have revealed that COPD patients with similar levels of FEV1 experienced different 
degrees of disease burden reflected by dyspnoea levels, exacerbations rates, health-related 
quality of life (HRQoL) impairment and exercise limitation [3]. Accordingly, the current 
classification of COPD proposed by the Global initiative for chronic Obstructive Lung Disease 
(GOLD) incorporates not only FEV1 but also dyspnoea or HRQoL, and previous occurrence of 
COPD exacerbations and/or hospitalization [1]. Although this classification is not fully 
evidence-based, it has the advantage of taking into account some of the clinical heterogeneity 
of COPD with the aim of predicting future risk and proposing corresponding treatment choices. 
A limitation of this classification is that it does not account for age, an important determinant 
of prognosis in patients with COPD [4]. Further, the GOLD classification does not account for 
comorbidities, which are frequent and contribute to prognosis [5-7]. 
Several groups have used clusters analyses to explore clinical heterogeneity in cohorts of patient 
in COPD [8-10]. These studies have identified consistent clinical COPD phenotypes at high 
risk of mortality, including (i) younger patients with severe respiratory disease, few 
cardiovascular co-morbidities, and poor nutritional status, and (ii) older patients with moderate 
respiratory disease, metabolic and cardiovascular co-morbidities, and obesity [11]. They have 
also identified patients with mild disease and good prognosis [12, 13]. However, all published 
studies had limitations related to relatively small sample size and lack of further validation in 
independent samples [11, 13]. Further, the results of cluster analyses are difficult to translate 




In the present study, our aim was to develop and validate an algorithm, based on easily available 





Data from three French/Belgian COPD cohorts were used to identify clinical COPD phenotypes 
using cluster analysis. Classification and Regression Trees (CARTs) [14] analysis was then 
used to develop an algorithm for allocating individual COPD patients recruited in these 
French/Belgian cohorts to specific subgroups. This algorithm was further tested in an 
independent sample of patients with COPD, using data from the COPD Cohorts Collaborative 
International Assessment (3CIA) initiative [15]. 
 
COPD patient cohorts  
The French/Belgian COPD cohorts are composed of three cohorts: the INITIATIVES BPCO 
cohort [8], the French College of General Hospital Respiratory Physicians (CPHG) cohort [16], 
and the Leuven cohort [12]. Patients within these cohorts have a diagnosis of COPD based on 
post-bronchodilator FEV1/FVC<0.70 and were recruited in stable state in university hospitals 
(INITIATIVES BPCO and Leuven cohorts) [8, 12] or at the time of hospitalization for COPD 
exacerbations (CPHG cohort) [16], as previously described. The COPD Cohorts Collaborative 
International Assessment (3CIA) initiative contains pooled individualized data from 22 cohorts 
of patients with COPD, who were recruited in publicly-funded hospitals or in population based-
studies [15]. All cohorts were approved by local Ethics Committee and all subjects provided 
informed written consent.  
 
Statistical analysis plan 
First, COPD patients recruited in the French/Belgian cohorts were classified into subgroups 
based on the results of a cluster analysis of data obtained at inclusion in the cohorts. The clinical 
relevance of the identified subgroups was established by examining their association with 3-
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year all-cause mortality. Next, CARTs were used for the development of an algorithm, 
assigning COPD patients to the subgroups identified by cluster analysis. The clinical value of 
this algorithm was examined using 3-year all-cause mortality in the French/Belgian cohorts. 
Finally, the algorithm was tested for external validation using data from the 3CIA initiative 
database [15]. Mortality risks among subgroups were analysed using Kaplan-Meier curves and 
Cox models. Concordance Probability Estimate (CPE) was used to evaluate the discriminatory 
power of classifications for mortality prediction. Data are presented as median (interquartile 
range, IQR) or n (%). Analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC, 
USA) and Tanagra 1.4 (Lyon, France) softwares. Additional information on the methods can 
be found in the online supplement to this manuscript. 
 
Cluster analysis of the French/Belgian COPD cohorts 
Variables were selected for inclusion in the cluster analysis based on their previous association 
with future risk and prognosis in COPD patients [1, 6] and included age, body mass index 
(BMI), FEV1 (% predicted), modified Medical Research Council (mMRC) dyspnoea scale, 
number of exacerbations in the previous 12 months, and presence/absence of cardiovascular 
comorbidities (hypertension, coronary artery disease and/or left heart failure) and/or diabetes. 
Identification of subgroups of patients with COPD associated with survival was achieved using 
factor analysis for mixed data (FAMD) [17, 18], followed by classification of patients using 
Ward’s agglomerative hierarchical cluster analysis [8, 12]. The clinical relevance of the 
identified subgroups was examined by comparing their all-cause mortality at three years, as 
described previously [8, 12]. These subgroups (phenotypes) were labelled using Roman 
numbers. 
 




The development of an algorithm for assigning COPD patients to the subgroups identified by 
cluster analysis was achieved using CART analysis [14, 19], a non-parametric decision tree 
learning technique [19]. Variables included in this analysis were those selected for the cluster 
analysis (see above). Threshold values for these variables were based on those obtained by 
CART analysis and were slightly modified for improved practicality (see online supplement for 
a detailed explanation).   
 
External validation of the algorithm 
The algorithm established in the French/Belgian cohorts was then tested in an independent 
group of patients with COPD from the 3CIA database. Patients in this database (n=16332) were 
considered eligible for the study if data necessary to apply the algorithm (age, BMI, FEV1 % 
predicted, mMRC scale, presence/absence of cardiovascular comorbidities and diabetes) and 
information on vital status at three years were available. Patients with appropriate data (n=3651) 
were classified by the algorithm into the five classes described above (labelled using Arabic 
digits), and these classes were compared according to their clinical characteristics, all-cause 







Patients and overall study design 
Study design is explained in Figure 1 and characteristics of patients with COPD at inclusion in 
the French/Belgian cohorts (n=2409 patients) and in the 3CIA database (n=3651 patients) are 
presented in Table S1. Their 3-year all-cause mortality rates were 30.8% and 11.6%, 
respectively. Patients included in the French/Belgian cohorts were characterized by older age, 
more severe airflow limitation and higher rates of cardiovascular comorbidities and/or diabetes. 
Further, 57% of patients in the French/Belgian cohorts were recruited at the time of 
hospitalization for COPD exacerbations (as part of the CHPG cohort) [16].  
 
Cluster analysis of the French/Belgian cohorts 
Table 1 shows the five subgroups (labelled I to V) identified in the French/Belgian COPD 
cohorts using cluster analysis (see online supplement, Table S2 to S6 and Figure S1). Table 2 
summarizes the main descriptors of these subgroups according to increasing rates of 3-year all-
cause mortality. Subgroup V (mortality rate, 2.5%) was characterized by mild respiratory 
disease and low rates of comorbidities. Subgroup II (mortality rate, 21.8%) was characterized 
by moderate to severe respiratory disease and low rates of comorbidities. Subgroup III 
(mortality rate, 30.0%) was characterized by older age than subgroup II, with high prevalence 
of comorbidities and obesity. Subgroup IV (mortality rate, 47.0%) was characterized by very 
severe respiratory disease with low rates of cardiovascular comorbidities and diabetes. 
Subgroup I (mortality rate, 50.9%) had less severe respiratory disease than subgroup IV but had 
older age and very high rates of cardiovascular comorbidities and diabetes.    
 
Use of CART for the development of an algorithm assigning COPD patients to subgroups 
of patients identified by cluster analysis in the French/Belgian cohorts 
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CART analysis provided an algorithm that allowed assigning up to 80% of the patients to the 
subgroups identified by cluster analysis (see online supplement, Table S7 and S8). This 
algorithm is presented in Figure 2 and clinical characteristics of patients according to the five 
classes obtained by applying this algorithm are presented in Table 3. Kaplan-Meier survival 
curves by cluster analysis-defined subgroups (Figure 3A) and by CART-defined classes 
(Figure 3B) showed comparable results. Concordance probability estimates were 0.61 (95% 
CI; 0.59 – 0.63) for cluster analysis-defined subgroups and 0.60 (95% CI; 0.58 – 0.62) for 
CART-defined classes, confirming that both methods had comparable discriminatory power for 
the identification of subgroups with different prognosis. 
 
Evaluation of the algorithm using data from the 3CIA initiative database 
The algorithm developed in the French/Belgian cohorts was then tested using data obtained in 
COPD patients from the 3CIA database. Characteristics of the 3651 patients distributed into 
classes according to this algorithm are presented in Table 3. Kaplan-Meier survival curves by 
classes are presented in Figure 3C. The concordance probability estimates was 0.62 (95% CI; 
0.59 – 0.64). 
 
Comparison of mortality rates among classes in the French/Belgian COPD cohorts vs. 
3CIA database 
Because 3-year mortality rates varied widely between French/Belgian COPD cohorts and the 
3CIA database, we used Cox analysis to examine hazard ratios of mortality among patients in 
the five classes defined by our algorithm in the French/Belgian and 3CIA cohorts, respectively. 
Forest plots corresponding to these analyses are presented in Figure 4. Although absolute rates 
of death were markedly higher in the French/Belgian cohorts, hazard ratios of mortality among 
the five classes were rather comparable in the French/Belgian cohorts and in the 3CIA initiative. 
12 
 
Distribution by GOLD grades of severity of airflow limitation [1] in patients who died during 
follow-up is presented in Figure 5. When comparing classes with high rates of all-cause 
mortality, patients without cardiovascular comorbidities/diabetes (class 4) who died were 
predominantly in GOLD 4 whereas patients with cardiovascular comorbidities/diabetes (class 
1) who died had less severe airflow limitation (predominantly GOLD 2 and 3). Comparable 





In the present study, we first performed a cluster analysis in a pool of French/Belgian COPD 
cohorts, which identified five subgroups (phenotypes) of patients with different rates of all-
cause mortality at 3 years and different age at death. We then used CART analysis in this pool 
of French/Belgian cohorts to develop an algorithm that allowed allocation of patients into five 
classes, corresponding to the subgroups identified by cluster analysis. This simple algorithm 
was based on clinical variables (including cardiovascular comorbidities and/or diabetes and 
respiratory characteristics) routinely available in daily practice. Classification of COPD patients 
using this algorithm allowed the identification of subgroups of patients differing on 3-year all-
cause mortality and age at death in the pool of French/Belgian cohorts, providing internal 
validation of the approach. It provided comparable results in patients included in the 3CIA 
initiative database, which contained an independent group of patients with COPD recruited in 
multinational cohorts, providing external validation. This algorithm identifies clinical 
phenotypes relevant to prognosis in patients with COPD, which could help exploring 
underlying pathophysiological mechanisms and developing novel strategies of care. 
The algorithm described in the present study is the first to integrate comorbidities 
(cardiovascular diseases, diabetes, and obesity) and age to more classical respiratory variables 
(FEV1 and dyspnoea) for improving the characterization of patients with COPD. An important 
yield of this algorithm is to identify patients belonging to two subgroups with poorer prognosis, 
i.e. class 1 and 4, and to highlight the corresponding determinants, i.e., the severity of the 
respiratory component (as assessed by the degrees of lung function impairment and dyspnoea) 
and the presence of major cardiovascular comorbidities or metabolic risk factors (diabetes). 
This data confirm previous studies showing that (A) cardiovascular and metabolic 
comorbidities contribute to worsen outcomes (e.g., mortality, hospitalization and exacerbation) 
in patients with COPD [6, 20] and (B) two very different phenotypes of COPD patients at poor 
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prognosis exist (those with severe respiratory disease, often occurring at a younger age and 
those with multimorbidity including cardiovascular and metabolic diseases, often characterized 
by an older age) [9, 12]. Importantly, this study extends previous data by studying larger 
numbers of patients (including larger numbers of women) recruited in multiple countries and 
provides a simple algorithm that can be used in the clinic for classifying the patients. One yield 
of the algorithm is to highlight the variables on which clinicians and researchers should focus 
during follow-up and treatment adaptation. Whether specific strategies need to be developed 
for all or some of the identified phenotypes now needs to be tested prospectively. Similarly, 
future studies should aim at determining whether these phenotypes are associated with specific 
biomarkers reflecting underlying pathophysiological mechanisms.  
The main strengths of the present study were the application of exploratory statistical analyses 
complemented by clinical knowledge in large cohorts of patients, the validation of findings in 
an external pool of cohorts and the use of a robust variable (mortality) for validation. We also 
recognize that the present study has limitations. Our assessment of comorbidities was based on 
physician diagnoses, not taking into account occult conditions, which are reported to occur in 
COPD patients [21]. To limit such underestimation of the impact of undiagnosed cardiovascular 
diseases, the definition of cardiovascular comorbidities was relatively loose and included 
hypertension (a risk factor for cardiovascular disease rather than a disease itself). This definition 
also corresponds to what happens in real-life daily practice, where many patients do not benefit 
from systematic screening for cardiovascular comorbidities. Although COPD patients are at 
high risk of lung cancer, which is associated with poor prognosis, patients with active lung 
cancer were generally excluded from the present cohorts, limiting our findings to COPD 
patients without active lung cancer. Specific causes of mortality were not available in the 
cohorts used in the present analyses and the prognostic value of the phenotypes was confirmed 
using all-cause mortality. Previous studies showed that causes of mortality in COPD 
15 
 
populations differ between patients with mild vs. severe airflow obstruction, with a higher 
relative weight of cancer and cardiovascular causes in patients with less severe airflow 
impairment, and more respiratory causes in the more severe [22]. Among patients who died, 
differences in the GOLD grades of airflow obstruction (see Figure 4) between phenotypes with 
comparable survival rates (e.g., class 1 vs. class 4 and class 2 vs. class 3) suggest that patients 
with high rates of cardiovascular comorbidities and/or diabetes (e.g., class 1 and 3) were more 
likely to die from extrapulmonary causes. Importantly, even if one of its properties is to identify 
populations with different mortality rates, the algorithm is not intended at representing a 
prognostic index, since the determinants of a given prognosis might differ markedly between 
patients of a given group. The large difference in mortality rates between the two groups of 
cohorts largely relates to the fact that 57% of patients in the French/Belgian cohorts were 
recruited at the time of hospitalization for a COPD exacerbation (CPHG cohort) [16], reflecting 
the prognostic impact of hospitalizations. Although hospitalization appears an important 
prognostic factor, it should be considered a marker of disease severity rather than a phenotype 
per se. This was the basis for not including previous hospitalisation as a variable in the cluster 
analysis. However, COPD exacerbations (which are important in the characterization of 
patients with COPD) [23] were included in the cluster analysis and in the CART analysis. The 
finding that exacerbations were not retained in our final algorithm should not be misinterpreted 
as exacerbations remain important events in the life of patients with COPD [24]; it merely 
reflects that non-hospitalized exacerbations were not significantly related to prognosis. The 
performance of classification trees could also be improved by the integration of biomarkers 
reflecting inflammatory (fibrinogen, white blood cell count, CRP, eosinophils…) [25-27] and 
cardiovascular (BNP, copeptin, pro-adrenomedullin…) [28] biological phenomena.  
The field of COPD phenotypes was once considered “the future of COPD” [29], but moving 
from exploratory research studies to the clinic has proven difficult. The algorithm described in 
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the present study offers a new way of combining and hierarchizing well-known prognostic 
criteria (including comorbidities, age and symptoms) to identify COPD phenotypes in the clinic. 
This approach may serve as a basis for developing phenotype-specific therapeutic strategies by 
recruiting appropriate at-risk target populations in clinical trials. We speculate that our 
algorithm may also help in unravelling specific biological pathways that were previously 
missed due to mixing of various phenotypes in the current classifications of COPD.  
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Table 1. Characteristics and 3-year mortality in COPD patients (n=2409) recruited in 















Male gender 82% (499) 76% (662) 80% (263) 75% (215) 78% (246) 
Age, years 77 [71 ; 81] 64 [57 ; 73] 74 [69 ; 80] 64 [57 ; 71] 61 [57 ; 67] 
BMI 25 [22 ; 28] 24 [20 ; 27] 30 [27 ; 34] 20 [18 ; 23] 26 [24 ; 29] 
Obesity >30 kg/m2 14.8% (90) 9.6% (84) 49.5% (162) 2.8% (8) 19.4% (61) 








18 %  
43 %  
39 %  
 
3 %  
35 %  
43 %  
19 %  
 
7 %  
67 %  
21 %  
4 %  
 
0 % 
4 %  
31 %  
65 %  
 
44 %  
51 %  
5 %  
0 %  
mMRC dyspnoea scale 3 [3 ; 4] 2 [1 ; 2] 2 [1 ; 2] 3 [3 ; 4] 1 [0 ; 1] 
Exacerbations/patient/year 2 [1 ; 3] 1 [0 ; 2] 1 [0 ; 2] 2 [2 ; 4] 0 [0 ; 1] 
Hospitalizations/patient/year 1 [0 ; 2] 0 [0 ; 1] 0 [0 ; 1] 1 [0 ; 2] 0 [0 ; 0] 
Any cardiovascular disease 
or diabetes 
91% (554) 19% (165) 96% (315) 6% (17) 26% (83) 
Specific comorbidities 
Coronary artery disease 
Hypertension 



























3-year mortality, % (n) 50.9% (310) 21.8% (190) 30.0% (98) 47.0% (135) 2.5% (8) 
Age at death, years 79 [74 ; 84] 70 [61 ; 79] 79 [74 ; 84] 69 [63 ; 75] 65 [60 ; 71] 
 
 
Table 2. Main descriptors of the 5 COPD phenotypes identified by cluster analysis in the 







Phenotype number V II III IV I 
3-year mortality rate 2.5% 21.8% 30.0% 47.0% 50.9% 










Airflow limitation Mild to 
moderate 
Moderate to  
very severe 
Mild to  
severe 
Severe to  
very severe 
Moderate to  
very severe 































Very low Very high 
 
Median age (years) 61 64 74 64 77 





Table 3. Characteristics and 3-year mortality rates in COPD patients recruited in the 
French/Belgian COPD cohorts or in the 3CIA initiative database according to the five 
classes identified using the CART-based algorithm 
 
 
French/Belgian cohorts (n=2409) 
  
Class 1 
n= 648 (27%) 
Class 2 
n= 981 (41%) 
Class 3 
n= 283 (12%) 
Class 4 
n= 267 (11%) 
Class 5 
n= 230 (10%) 
Male gender 81 % 76 % 83 % 78 % 76 % 
Age, years 75 [70; 80] 65 [58; 73] 74 [66; 79] 66 [59; 74] 61 [57; 68] 
BMI 25 [22; 29] 24 [21; 28] 30 [25; 33] 21 [19; 25] 25 [23; 28] 
Obesity >30 kg/m2 19 % 11 % 46 % 9 % 10 % 































mMRC dyspnoea scale 3 [3 ; 3] 2 [1 ; 2] 2 [1; 2] 3 [3; 4] 1 [0; 1] 
Exacerbations/patient/year 2 [1; 3] 1 [0; 2] 1 [0; 2] 2 [1; 3] 0 [0; 1] 
Hospitalizations/patient/year 1 [0 -   2] 0 [0 -   1] 0 [0 -   1] 1 [0 -   2] 0 [0 -   0] 
Any cardiovascular 
comorbidity or diabetes 
100 % 21 % 100 % 0 % 0 % 
3-year mortality 50 % 23 % 24 % 45 % 3 % 
Age at death, years 78 [73; 83] 72 [64; 80] 79 [71; 84] 71 [65; 76] 71 [61; 72] 
 












Male gender 66 % 66 % 73 % 71 % 53 % 
Age, years 71 [63; 76] 63 [57; 68] 72 [64; 76] 64 [58; 71] 59 [51; 66] 
BMI 26 [23; 30] 25 [22; 28] 30 [25; 32] 24 [21; 27] 25 [22; 27] 
Obesity >30 kg/m2 24 % 11 % 48 % 7 % 10 % 































mMRC dyspnoea scale 4 [2 ; 4] 1 [1 ; 2] 1 [0 ; 2] 4 [4 ; 4] 0 [0 ; 1] 
Any cardiovascular 
comorbidity or diabetes 
100 % 35 % 100 % 0 % 0 % 
3-year mortality 23 % 11 % 14 % 27 % 4 % 





LEGENDS OF FIGURES 
Figure 1. Study design. Patients with COPD recruited in the French/Belgian cohorts were 
classified into subgroups (phenotypes) based on the results of a cluster analysis of clinical data 
obtained at inclusion in the cohorts. Next, CARTs were used on the same data to determine the 
best variables and thresholds necessary for the development of an algorithm for assigning 
COPD patients to the subgroups identified by cluster analysis in the French/Belgian cohorts. 
This analysis lead to the development of a simple algorithm for allocating patients with COPD 
into 5 classes. This algorithm was then tested for external validation using data from the 3CIA 
initiative database (n=16332). This latter analysis was only possible in patients with available 
data (n=3651), i.e. with all the variables contained in the algorithm. In each analysis, the clinical 
relevance of the identified subgroups/classes was established by examining their association 
with 3-year all-cause mortality. 
 
Figure 2. Algorithm developed by CART-analysis for the classification of COPD patients. 
Application to the French/Belgian and 3CIA cohorts. 
 
Figure 3. Kaplan-Meier analyses for assessing all-cause mortality at three years.  
3A: French/Belgian COPD cohorts according to the five subgroups (phenotypes, Ph) identified 
by cluster analysis.  3B: French/Belgian COPD cohorts according to the five classes identified 
by CART analysis. 3C: 3CIA COPD cohort according to the five classes identified by the 
algorithm developed in the French/Belgian cohorts. All analyses, P<0.0001 (Log-rank test). 
 
Figure 4. Relative mortality risks at three years among COPD patients in the 
French/Belgian COPD cohorts (A) and in the 3CIA initiative (B). COPD patients were 
classified into five classes according to the algorithm. Horizontal bars show hazard ratios and 
22 
 
95% confidence intervals of mortality risks between classes. For example, in the 
French/Belgian COPD cohorts, subjects in class 4 have a 23.2-fold (95% CI 10.2–52.7) 
increased risk of mortality when compared with subjects in class 5. 
 
Figure 5. Distribution of airflow limitation severity by GOLD grade at inclusion in the 
cohorts in patients who died during follow-up. A. French/Belgian cohorts. B. 3CIA 
initiative. Data are presented as % of the total number of death in each class. Absolute numbers 
of deaths (n) in each class are also presented. 
